Prudent Man Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.53M Buy
3,427
+1,298
+61% +$605K 0.46% 56
2025
Q4
$965K Buy
2,129
+578
+37% +$249K 0.35% 61
2025
Q3
$607K Sell
1,551
-184
-11% -$76.9K 0.22% 88
2025
Q2
$772K Buy
1,735
+376
+28% +$173K 0.25% 93
2025
Q1
$659K Sell
1,359
-403
-23% -$188K 0.24% 100
2024
Q4
$710K Sell
1,762
-122
-6% -$56.6K 0.26% 84
2024
Q3
$876K Sell
1,884
-124
-6% -$59.6K 0.29% 85
2024
Q2
$941K Buy
2,008
+74
+4% +$32.1K 0.33% 69
2024
Q1
$808K Sell
1,934
-123
-6% -$52K 0.3% 79
2023
Q4
$837K Sell
2,057
-30
-1% -$11.1K 0.31% 71
2023
Q3
$726K Sell
2,087
-71
-3% -$24.8K 0.29% 79
2023
Q2
$759K Sell
2,158
-30
-1% -$10.1K 0.29% 74
2023
Q1
$689K Sell
2,188
-25
-1% -$7.5K 0.27% 84
2022
Q4
$639K Buy
2,213
+588
+36% +$179K 0.26% 98
2022
Q3
$471K Sell
1,625
-12
-0.7% -$3.45K 0.22% 95
2022
Q2
$461K Sell
1,637
-28
-2% -$7.49K 0.22% 95
2022
Q1
$435K Sell
1,665
-59
-3% -$14K 0.18% 105
2021
Q4
$379K Sell
1,724
-3
-0.2% -$583 0.14% 114
2021
Q3
$313K Sell
1,727
-21
-1% -$4.1K 0.12% 136
2021
Q2
$352K Buy
1,748
+53
+3% +$11.1K 0.14% 122
2021
Q1
$364K Buy
1,695
+83
+5% +$18.2K 0.15% 116
2020
Q4
$381K Sell
1,612
-31
-2% -$7.11K 0.16% 110
2020
Q3
$447K Buy
1,643
+54
+3% +$14.9K 0.24% 87
2020
Q2
$461K Buy
+1,589
New +$431K 0.41% 70

Other funds holding VRTX

Prudent Man Advisors's VRTX Position: Q1 2026 in Review

Prudent Man Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 61% in Q1 2026, buying an estimated $605K and bringing the position to 3,427 shares worth $1.53M. The position accounts for 0.46% of the portfolio, ranked #56.

Prudent Man Advisors first reported a position in VRTX in Q2 2020 and has held it in 24 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Prudent Man Advisors held 3,427 shares of Vertex Pharmaceuticals worth $1.53M as of Q1 2026.
  • Prudent Man Advisors bought 1,298 Vertex Pharmaceuticals shares in Q1 2026, an estimated $605K.
  • Vertex Pharmaceuticals made up 0.46% of Prudent Man Advisors's portfolio in Q1 2026, its #56 holding.
  • Prudent Man Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Prudent Man Advisors's 13F filing for Q1 2026, filed 8 May 2026.